Article Text


FRI0075 Comp levels in serum lowered after six months treatment with etanercept in patients with rheumatoid arthritis
  1. Å Thörner1,
  2. C Freiburghaus2,
  3. S Ernestam1,
  4. J Bratt1
  1. 1Department of Rheumatology, Huddinge University Hospital, Stockholm
  2. 2AnaMar, Med., Lund, Sweden


Objectives The aim of this study was to evaluate Cartilage Oligometric Matrix Protein (COMP) levels during TNFalfa-blocking therapy with Etanercept (Enbrel) in patients with rheumatoid arthritis (RA). Previous studies have suggested that serum COMP levels is a marker for joint destruction in RA.

Methods 38 patients (34 female, 4 male) with active, longstanding RA were treated with Etanercept 25 mg x2/week. The efficacy measures included ACR response rates after treatment for 3 and 6 months. COMP was measured in serum using sandwich ELISA from AnaMar Med. Lund. Wilcoxon Matched Paired Test was used for statistical analysis.

Results ACR 20, 50 and 70 responses were demonstrated for 79%, 29% and 5% of the patients, respectively, at 3 months and 68%, 35% and 11% at 6 months. 21% of the patients were still non-responders to Etanercept at 3 months and 32% after 6 months. The ACR response rates at 12 months will be presented at the meeting. A significant decrease (p < 0,05) in serum COMP levels was seen after 6 and 12 months treatment with Etanercept but not after 3 months. At 3 months COMP levels showed a high degree of variability.

Conclusion Significant reduction in serum COMP levels were seen after six months TNFalfa-blocking therapy and was maintained after 12 months. The COMP levels at 3 months gave no indication regarding outcome of treatment.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.